OBI Shares Opportunities and Challenges of ADC Development at BioAsia2024

Antibody-drug conjugates (ADCs) have emerged as a promising new treatment for cancer. With record-breaking transaction volumes in international mergers and acquisitions, many domestic biotechnology companies have also entered this field. On July 24th, Dr. Heidi Wang, CEO of OBI Pharma (4174.TWO), was invited to speak at the "Opportunities and Challenges of ADC Development" forum at the BioAsia Exhibition.